v3.22.2.2
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Non- controlling Interest
Beginning balance at Sep. 30, 2019 $ 244,036 $ 188 $ 664,086 $ (392) $ (419,291) $ (555)
Beginning balance (in shares) at Sep. 30, 2019   95,506,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 43,383   43,383      
Exercise of stock options 7,469 $ 1 7,468      
Exercise of stock options (in shares)   1,111,000        
Common stock - restricted stock units vesting 0 $ 1 (1)      
Common stock - restricted stock units vesting (in shares)   1,159,000        
Common stock - issued for cash 250,479 $ 5 250,474      
Common stock - issued for cash (in shares)   4,600,000        
Foreign currency translation adjustments 410     410    
Deconsolidation of Ablaris Therapeutics, Inc. 555         555
Net loss (84,553)       (84,553)  
Ending balance at Sep. 30, 2020 461,779 $ 195 965,410 18 (503,844) 0
Ending balance (in shares) at Sep. 30, 2020   102,376,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 76,673   76,673      
Exercise of stock options 11,305 $ 1 11,304      
Exercise of stock options (in shares)   1,052,000        
Common stock - restricted stock units vesting 0 $ 1 (1)      
Common stock - restricted stock units vesting (in shares)   899,000        
Foreign currency translation adjustments (87)     (87)    
Net loss (140,848)       (140,848)  
Ending balance at Sep. 30, 2021 408,822 $ 197 1,053,386 (69) (644,692) 0
Ending balance (in shares) at Sep. 30, 2021   104,327,000        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Stock-based compensation 120,893   120,893      
Exercise of stock options $ 5,185   5,185      
Exercise of stock options (in shares) 606,220 606,000        
Common stock - restricted stock units vesting $ 0 $ 1 (1)      
Common stock - restricted stock units vesting (in shares)   1,027,000        
Foreign currency translation adjustments (67)     (67)    
Interest in joint venture 60,000   39,750     20,250
Net loss (176,494)       (176,063) (431)
Ending balance at Sep. 30, 2022 $ 418,339 $ 198 $ 1,219,213 $ (136) $ (820,755) $ 19,819
Ending balance (in shares) at Sep. 30, 2022   105,960,000